Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin.

Abstract : Doxorubicin and other anthracyclines are among the most potent chemotherapeutic drugs for the treatment of acute leukaemia, lymphomas and different types of solid tumours such as breast, liver and lung cancers. Their clinical use is, however, limited by the risk of severe cardiotoxicity, which can lead to irreversible congestive heart failure. There is increasing evidence that essential components of myocardial energy metabolism are among the highly sensitive and early targets of doxorubicin-induced damage. Here we review doxorubicin-induced detrimental changes in cardiac energetics, with an emphasis on the emerging importance of defects in energy-transferring and -signalling systems, like creatine kinase and AMP-activated protein kinase.
Type de document :
Article dans une revue
Comptes Rendus Biologies, Elsevier Masson, 2006, 329 (9), pp.657-68. 〈10.1016/j.crvi.2005.08.007〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00390889
Contributeur : Sarah Hamant <>
Soumis le : mercredi 3 juin 2009 - 00:06:42
Dernière modification le : mardi 7 juillet 2009 - 12:50:12

Identifiants

Collections

Citation

Malgorzata Tokarska-Schlattner, Théo Wallimann, Uwe Schlattner. Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin.. Comptes Rendus Biologies, Elsevier Masson, 2006, 329 (9), pp.657-68. 〈10.1016/j.crvi.2005.08.007〉. 〈inserm-00390889〉

Partager

Métriques

Consultations de la notice

46